-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PD-1/CTLA-4 combined blockade and BRAF/MEK double inhibition have shown significant clinical benefit
In a Phase 3 clinical trial, untreated BRAFV600 mutant metastatic melanoma was randomly divided into two groups, the first step receiving nalvozumab + ipizumab (group A) or dalafinil + trametinib (group B), and after the progression of the disease, proceeding to the second step, switching to a treatment regimen, dalafinil + trametinib (group C) or nalvozumab + ipizumab (group D).
A total of 265 patients were recruited and 73 were enrolled in the second step of treatment (27 in group C and 46 in group D
In summary, if necessary, nivolumab plus ipizumab followed by BRAF and MEK inhibitors may be the order
Original Source:
Michael B.